Pfizer announces positive dermatitis therapy phase III results

Pfizer has announced that its investigational oral Janus kinase 1 (JAK1) inhibitor abrocitinib (PF-04965842) has met all co-primary and secondary endpoints in a pivotal Phase III study evaluating safety and efficacy in patients aged 12 and older with moderate to severe atopic dermatitis. The positive top-line results came from a randomised, double-blind, placebo-controlled, parallel-group study designed to evaluate the efficacy and safety of two doses - 100mg and 200mg once daily - of abrocitinib monotherapy over 12 weeks. By week 12 the percentage of patients achieving each co-primary efficacy endpoint and each key secondary endpoint with either dose of abrocitinib was statistically significantly higher than placebo, demonstrating response to treatment for a statistically significant number of patients during the first two to four weeks following first dose.